Capricor Therapeutics, Inc. - Common Stock (CAPR)

If CAP-1002 (Deramiocel) is approved on schedule, deramiocel would become the first therapy indicated specifically for DMD-associated cardiomyopathy, addressing a critical unmet need. The StealthX(tm) exosome delivery system is a momentous change.

Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028).

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.

The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027.

The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.

FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues.

Today’s macro environment reflects a strong risk-on sentiment, fueled by a notable rally in Bitcoin, which has surged past the $90,000 threshold.

Capricor Therapeutics shares are trading lower by 2.7% during Thursday's session. The company earlier commenced its public offering of common stock.

Capricor Therapeutics announced promising 3-year results from its HOPE-2 extension study for deramiocel in treating Duchenne muscular dystrophy, showing significant cardiac and motor function improvements.